Amgen's DMab scores in trials

For the biotech, a new drug for bone cancer and osteoporosis could mean a big boost in revenue.

EMAIL  |   PRINT  |   SHARE  |   RSS
 
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)
By Alyssa Abkowitz, reporter

Inside a biotech giant
Through video and animation, see how Amgen's research leads to breakthrough pharmaceuticalsMore
How much did you spend out of pocket for health care last year?
  • Under $1,000
  • $1,000 to $5,000
  • $5,000 to $10,000
  • More than $10,000

NEW YORK (Fortune) -- An Amgen trial drug -- called denosumab -- reached a new milestone on July 7 when the biotechnology company announced results from the latest clinical trial of the drug for bone cancer. The trial of more than 2,000 patients showed DMab -- which works to slow bone destruction, a primary concern for people with advanced cancer and the cause of a myriad of complications, including fractures -- delayed the time it took for damage to occur when compared to rival drug Zometa, which is made by Novartis. Amgen has already submitted DMab to the Food and Drug Administration as a treatment for osteoporosis.

"We're very, very excited about it," Amgen CEO Kevin Sharer told Fortune. "This has been a drug we've worked on for 15 years. We did the fundamental biology and invested over $1 billion. I bet my job on it."

Talkback: What should Amgen focus on?

Yesterday, the day after the announcement, Amgen's stock surged 14% -- the most in four years. Analysts had a field day in their notes, with some increasing Amgen's share price expectations to more than $70 and others upping annual revenue estimates for DMab to as high as $3 billion.

Steve Yoo, an analyst at health care investment bank Leerink Swann, estimated in a note that U.S. sales of DMab as a treatment for bone cancer could hit $558 million by 2012. And U.S. sales of the drug as an osteoporosis therapy could total more than $2 billion in the same period, for an overall DMab revenue of more than $3 billion by Yoo's calculations.

By comparison, Zometa brought in $1.4 billion in sales last year. Yoo noted that the cost of DMab will likely be higher than Zometa, but warned that pricing it too high could limit prescriptions of the drug as an osteoporosis treatment.

DMab is a biologic -- a medicine made from living organisms -- and works by blocking the activity of the protein that regulates the cells responsible for breaking down bone, making it valuable as an osteoporosis therapy. When used as a bone cancer treatment, it targets metastases that are extremely prevalent with certain types of advanced cancer, reaching incident rates of nearly 75% in breast and prostate cancer patients, according to Amgen (AMGN, Fortune 500).

The biotech expects an FDA decision on DMab as an osteoporosis therapy by Oct. 19. Yoo says there's no timeline yet on when the drug will be submitted to the agency for approval as a bone cancer treatment. But whenever the decisions arrive, approval of DMab for both uses would mean a big boost for Amgen. "I think it'll really be important for patients," Sharer told Fortune. "So it's very, very important to us." To top of page

Company Price Change % Change
Bank of America Corp... 16.13 -0.26 -1.59%
Facebook Inc 59.72 0.63 1.07%
Yahoo! Inc 36.35 -0.02 -0.06%
Intel Corp 26.93 0.16 0.60%
Alcoa Inc 13.42 0.37 2.84%
Data as of Apr 16
Index Last Change % Change
Dow 16,424.85 162.29 1.00%
Nasdaq 4,086.23 52.06 1.29%
S&P 500 1,862.31 19.33 1.05%
Treasuries 2.64 0.01 0.34%
Data as of 5:49am ET
More Galleries
8 CEOs who took a pay cut in 2013 Median CEO pay inched up 9% in 2013 to $13.9 million. But not everyone got a bump last year. Here are eight CEOs who missed out. More
7 businesses Amazon wants to shake up From industrial supplies to educational software, Amazon is about more than just retail and books. More
Don't miss these Tax Day deals From massages and paper shredding to cookies and queso, celebrate the end of tax season with these Tax Day freebies and discounts. More
Sponsors
Worry about the hackers you don't know 
Crime syndicates and government organizations pose a much greater cyber threat than renegade hacker groups like Anonymous. Play
GE CEO: Bringing jobs back to the U.S. 
Jeff Immelt says the U.S. is a cost competitive market for advanced manufacturing and that GE is bringing jobs back from Mexico. Play
Hamster wheel and wedgie-powered transit 
Red Bull Creation challenges hackers and engineers to invent new modes of transportation. Play

Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.